Asymptomatic PVCs with Normal Left Ventricular Function: To Ablate or Not to Ablate

Description

A debate on the management of asymptomatic PVCs in the setting of a normal EF. Discussion regarding the role of rhythm control.

Learning Objectives

Summarize the literature on PVC burden and outcomes, differences in the management of structural heart disease and normal hearts, and medical management options.
Enhance decision-making skills in the management of patients with asymptomatic PVCs.
Compare the outcomes of each type of management.

Session Chair(s)

Albert Sun, MD
David Frankel, MD

Presentation

Wait, Do NOT Ablate Those Asymptomatic PVCs
Presenter(s): Jean-Francois Sarrazin, MDCM

Asymptomatic PVCs with Normal Function: Ablate, Do Not Wait
Presenter(s): Gregory M. Marcus, MD

Rebuttal
Presenter(s): Jean-Francois Sarrazin, MDCM

Rebuttal
Presenter(s): Gregory M. Marcus, MD

Disclosures

Jean-Francois Sarrazin:

Biosense Webster, Inc. (Honoraria/Speaking/Consulting Fee - Consulting)
Abbott (Honoraria/Speaking/Consulting Fee - Consulting)

Gregory Marcus:

InCarda Therapeutics (Honoraria/Speaking/Consulting Fee - Consulting)
InCarda Therapeutics (Stocks – Publicly Traded - Ownership)

Jean-Francois Sarrazin:

Biosense Webster, Inc. (Honoraria/Speaking/Consulting Fee - Consulting)
Abbott (Honoraria/Speaking/Consulting Fee - Consulting)

Gregory Marcus:

InCarda Therapeutics (Honoraria/Speaking/Consulting Fee - Consulting)
InCarda Therapeutics (Stocks – Publicly Traded - Ownership)

To view all Heart Rhythm 2025 Faculty Disclosures, please click here.

Education Framework

Ventricular Tachyarrhythmias
-- Premature Ventricular Complexes (PVCs)
-- 220. Know when treatment of PVCs is indicated.

Summary


Availability:	No future session


Cost:	FREE


Credit Offered:	No Credit Offered